IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer

PLoS ONE

Volumn 12, Issue 4, 2017, Pages

  Rohena Rivera, Krizia ^a,b   Sanchez Vazquez, Maria M ^b   Aponte Colon, DIana A ^b   Forestier Roman, Ingrid S ^a,b   Quintero Aguilo, Mario E ^b   Martanez Ferrer, Magaly ^a,b  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALPHA SMOOTH MUSCLE ACTIN; CD14 ANTIGEN; CD31 ANTIGEN; CYCLIN D1; DESMIN; FAS LIGAND; INSULIN RECEPTOR SUBSTRATE 1; INTEGRIN LINKED KINASE; INTERLEUKIN 15; LEUKOCYTE ELASTASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE 3 KINASE CATALYTIC GAMMA POLYPEPTIDE; RAC1 PROTEIN; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL MOTILITY; CONTROLLED STUDY; CPT2 GENE; DTX1 GENE; GATA3 GENE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC REGULATION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID METABOLISM; LIPID STORAGE; MALE; METASTASIS; METASTASIS INHIBITION; MICROARRAY ANALYSIS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PLCG2 GENE; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAC1 GENE; REGULATORY MECHANISM; TUMOR GROWTH; TUMOR INVASION; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE; PROSTATE TUMOR; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERLEUKIN-15; LIPID METABOLISM; MALE; MICE; MICE, INBRED ICR; MICE, SCID; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 85017006149     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0172786     Document Type: Article

References (63)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29. https://doi. org/10.3322/caac.21254 PMID: 25559415
2. Freedland SJ, Humphreys EB, Mangold L a, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. American Medical Association; 2005; 294: 433-9. https://doi.org/10.1001/jama.294.4.433 PMID: 16046649
3. Alva A, Hussain M. Intermittent androgen deprivation therapy in advanced prostate cancer. Curr Treat Options Oncol. 2014; 15: 127-36. https://doi.org/10.1007/s11864-013-0272-2 PMID: 24395278
4. Bruce JY, Lang JM, McNeel DG, Liu G. Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012; 10: 716-22. PMID: 23271258
5. Stephenson AJ, Kattan MW, Eastham J a, Dotan Z a, Bianco FJ, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol. 2006; 24: 3973-8. https://doi.org/10.1200/JCO.2005.04.0756 PMID: 16921049
6. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013; 8: e66855. https://doi.org/10.1371/journal.pone.0066855 PMID: 23826159
7. Bickers B, Aukim-Hastie C. New molecular biomarkers for the prognosis and management of prostate cancer the post PSA era. Anticancer Res. 2009; 29: 3289-98. PMID: 19661347
8. Wang J, He Q, Shao YG, Ji M. Chemokines fluctuate in the progression of primary breast cancer. Eur Rev Med Pharmacol Sci. 2013; 17: 596-608. PMID: 23543442
9. Vindrieux D, Escobar P, Lazennec G. Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer. 2009; 16: 663-73. https://doi.org/10.1677/ERC-09-0109 PMID: 19556286
10. Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, et al. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate. 2012; 72: 487-98. https://doi.org/10.1002/pros.21449 PMID: 21748755
11. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012; 33: 35-41. https://doi.org/10.1016/j.tips.2011.09.004 PMID: 22032984
12. Waldmann TA. Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol. 2014; 10: 1689-701. https://doi.org/10.1586/1744666X.2014.973856 PMID: 25359408
13. Wu Z, Xu Y. IL-15R alpha-IgG1-Fc enhances IL-2 and IL-15 anti-tumor action through NK and CD8+ T cells proliferation and activation. J Mol Cell Biol. 2010; 2: 217-22. https://doi.org/10.1093/jmcb/mjq012 PMID: 20671116
14. Liu D, Song L, Wei J, Courtney AN, Gao X, Marinova E, et al. IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest. 2012; 122: 2221-33. https://doi.org/10.1172/JCI59535 PMID: 22565311
15. Stephenson KB, Barra NG, Davies E, Ashkar AA, Lichty BD. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther. 2012; 19: 238-46. https://doi.org/10.1038/cgt.2011.81 PMID: 22158521
16. Morris JC, Ramlogan-Steel CA, Yu P, Black BA, Mannan P, Allison JP, et al. Vaccination with tumor cells expressing IL-15 and IL-15R? inhibits murine breast and prostate cancer. Gene Ther. Macmillan Publishers Limited; 2014; 21: 393-401. https://doi.org/10.1038/gt.2014.10 PMID: 24572789
17. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, et al. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res. 2008; 14: 7790-7. https://doi.org/10.1158/1078-0432.CCR-08-1716 PMID: 19047106
18. Liu A, Furusato B, Ravindranath L, Chen Y, Srikantan V, McLeod DG, et al. Quantitative analysis of a panel of gene expression in prostate cancer with emphasis on NPY expression analysis. J Zhejiang Univ Sci B. Zhejiang University Press; 2007; 8: 853-9. https://doi.org/10.1631/jzus.2007.B0853 PMID: 18257117
19. Marchion DC, Xiong Y, Chon HS, Al Sawah E, Bou Zgheib N, Ramirez IJ, et al. Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer. Am J Obstet Gynecol. NIH Public Access; 2013; 209: 576.e1-576.e16.
20. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer. Science (80-). 1997; 275: 1943-1947.
21. Phin S, Moore MW, Cotter PD. Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol. 2013; 3: 240. https://doi.org/10.3389/fonc.2013.00240 PMID: 24062990
22. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem. 2006; 97: 433-447. https://doi.org/10.1002/jcb.20696 PMID: 16267836
23. Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A, et al. Role of PTEN gene in progression of prostate cancer. Urol J. 2007; 4: 95-100. PMID: 17701929
24. Bibikova M, Chudin E, Arsanjani A, Zhou L, Garcia EW, Modder J, et al. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics. 2007; 89: 666-672. https://doi. org/10.1016/j.ygeno.2007.02.005 PMID: 17459658
25. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME) toward standards for microarray data. Nat Genet. 2001; 29: 365-371. https://doi.org/10.1038/ng1201-365 PMID: 11726920
26. Lsaacs JT, Hukku B. Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate. 1988; 13: 165-188. PMID: 3174494
27. Oliveros JC. Venny. An interactive tool for comparing lists with Venn's diagrams. [Internet]. Available: http://bioinfogp.cnb.csic.es/tools/venny/index.html
28. Yu P, Steel JC, Zhang M, Morris JC, Waitz R, Fasso M, et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A. 2012; 109: 6187-92. https://doi.org/10.1073/pnas.1203479109 PMID: 22474386
29. Wu J-P, Huang W-B, Zhou H, Xu L-W, Zhao J-H, Zhu J-G, et al. Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy. Asian J Androl. Medknow Publications; 2014; 16: 710-4. https://doi.org/10.4103/1008-682X.129131 PMID: 24875819
30. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling. Clin Cancer Res. 2002; 8: 2912-2923. PMID: 12231536
31. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, et al. Reactive Stroma as a Predictor of Biochemical-Free Recurrence in Prostate Cancer. Clin Cancer Res. 2003; 9: 4792-4801. PMID: 14581350
32. Parkin J, Cohen B. An overview of the immune system. Lancet. 2001; 357: 1777-1789. https://doi.org/10.1016/S0140-6736(00)04904-7 PMID: 11403834
33. Cassatella M a, McDonald PP. Interleukin-15 and its impact on neutrophil function. Curr Opin Hematol. 2000; 7: 174-7. PMID: 10786655
34. Hammond ME, Lapointe GR, Feucht PH, Hilt S, Gallegos CA, Gordon CA, et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol (Baltimore, Md 1950). 1995; 155: 1428-1433.
35. Kawabata K, Hagio T, Matsuoka S. The role of neutrophil elastase in acute lung injury. Eur J Pharmacol. 2002; 451: 1-10. PMID: 12223222
36. Pham CTN. Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol. 2006; 6: 541-50. https://doi.org/10.1038/nri1841 PMID: 16799473
37. Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence. Histopathology. 2012; 60: 199-215. https://doi.org/10.1111/j.1365-2559.2011.04033.x PMID: 22212087
38. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006; 83: 461S-465S. PMID: 16470013
39. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004; 15: 2792-800. https://doi.org/10.1097/01.ASN.0000141966. 69934.21 PMID: 15504932
40. Touvier M, Fezeu L, Ahluwalia N, Julia C, Charnaux N, Sutton A, et al. Association between prediagnostic biomarkers of inflammation and endothelial function and cancer risk: a nested case-control study. Am J Epidemiol. 2013; 177: 3-13. https://doi.org/10.1093/aje/kws359 PMID: 23171880
41. Quinn LS, Strait-Bodey L, Anderson BG, Argils JM, Havel PJ, ArgileÂs JM, et al. Interleukin-15 stimulates adiponectin secretion by 3T3-L1 adipocytes: Evidence for a skeletal muscle-to-fat signaling pathway. Cell Biol Int. 2005; 29: 449-457. https://doi.org/10.1016/j.cellbi.2005.02.005 PMID: 15951205
42. Barb D, Neuwirth A, Mantzoros CS, Balk SP. Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocr Relat Cancer. 2007; 14: 995-1005. https://doi.org/10.1677/ERC-06-0091 PMID: 18045951
43. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: A review of current evidence. Endocr Rev. 2012; 33: 547-594. https://doi.org/10.1210/er.2011-1015 PMID: 22547160
44. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology. 2005; 65: 1168-72. https://doi.org/10.1016/j.urology.2004.12.053 PMID: 15922427
45. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun. 2006; 340: 1158-66. https://doi.org/10.1016/j.bbrc.2005.12.103 PMID: 16403434
46. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol. 2008; 19: 34-41. https://doi.org/10.1016/j.semcdb.2007.07.003 PMID: 17707664
47. Garratt LW, Sutanto EN, Ling K-M, Looi K, Iosifidis T, Martinovich KM, et al. Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis. Eur Respir J. 2015; 46: 384-94. https://doi.org/10.1183/09031936.00212114 PMID: 25929954
48. Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 Is an Acute-Phase Protein. J Immunol. 2004; 172: 4470-4479. PMID: 15034063
49. Shudo K, Kinoshita K, Imamura R, Fan H, Hasumoto K, Tanaka M, et al. The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol. 2001; 31: 2504-11. https://doi.org/10.1002/1521-4141(200108)31:8&60;2504::AID-IMMU2504&62;3.0. CO;2-C PMID: 11500835
50. Assi K, Patterson S, Dedhar S, Owen D, Levings M, Salh B. Role of epithelial integrin-linked kinase in promoting intestinal inflammation: effects on CCL2, fibronectin and the T cell repertoire. BMC Immunol. 2011; 12: 42. https://doi.org/10.1186/1471-2172-12-42 PMID: 21806815
51. Tian L, Fang Y-X, Xue J-L, Chen J-Z. Four MicroRNAs Promote Prostate Cell Proliferation with Regulation of PTEN and Its Downstream Signals In Vitro. PLoS One. 2013; 8: e75885. https://doi.org/10.1371/journal.pone.0075885 PMID: 24098737
52. Meyer K, Albaugh B, Schoenike B, Roopra A. Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST. Mol Cell Biol. 2015; 35: 2991-3004. https://doi.org/10.1128/MCB.01149-14 PMID: 26100015
53. Fu G, Chen Y, Schuman J, Wang D, Wen R. Phospholipase C?2 plays a role in TCR signal transduction and T cell selection. J Immunol. 2012; 189: 2326-32. https://doi.org/10.4049/jimmunol.1103458 PMID: 22837484
54. Caraux A, Kim N, Bell SE, Zompi S, Ranson T, Lesjean-Pottier S, et al. Phospholipase C-gamma2 is essential for NK cell cytotoxicity and innate immunity to malignant and virally infected cells. Blood. 2006; 107: 994-1002. https://doi.org/10.1182/blood-2005-06-2428 PMID: 16204312
55. Nassar N, Cancelas J, Zheng J, Williams DA, Zheng Y. Structure-function based design of small molecule inhibitors targeting Rho family GTPases. Curr Top Med Chem. 2006; 6: 1109-16. PMID: 16842149
56. Skvortsov S, DudaÂs J, Eichberger P, Witsch-Baumgartner M, Loeffler-Ragg J, Pritz C, et al. Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC). Br J Cancer. 2014; 110: 2677-87. https://doi.org/10.1038/bjc.2014.221 PMID: 24786604
57. Serrano-Pertierra E, Cernuda-MorolloÂn E, LoÂpez-Larrea C. NKG2D-and CD28-mediated costimulation regulate CD8+ T cell chemotaxis through different mechanisms: the role of Cdc42/N-WASp. J Leukoc Biol. 2014; 95: 487-95. https://doi.org/10.1189/jlb.0613316 PMID: 24168855
58. Stanelle J, DoÈring C, Hansmann M-L, KuÈppers R. Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed/Sternberg cells. Blood. American Society of Hematology; 2010; 116: 4202-11. https://doi.org/10.1182/blood-2010-01-265827 PMID: 20660789
59. Van de Walle I, Dolens A-C, Durinck K, De Mulder K, Van Loocke W, Damle S, et al. GATA3 induces human T-cell commitment by restraining Notch activity and repressing NK-cell fate. Nat Commun. 2016; 7: 11171. https://doi.org/10.1038/ncomms11171 PMID: 27048872
60. Wang C, Collins M, Kuchroo VK. Effector T cell differentiation: Are master regulators of effector T cells still the masters? Curr Opin Immunol. Elsevier Ltd; 2015; 37: 6-10. https://doi.org/10.1016/j.coi.2015. 08.001 PMID: 26319196
61. Takaku M, Grimm SA, Wade PA. GATA3 in Breast Cancer: Tumor Suppressor or Oncogene? Gene Expr. 2015; 16: 163-8. https://doi.org/10.3727/105221615X14399878166113 PMID: 26637396
62. Xie B, Zhang P, Liu M, Zeng W, Yang J, Liu H. Deltex1 Polymorphisms Are Associated with Hepatitis B Vaccination Non-Response in Southwest China. PLoS One. 2016; 11: e0149199. https://doi.org/10. 1371/journal.pone.0149199 PMID: 26894927
63. Huber RM, Rajski M, Sivasankaran B, Moncayo G, Hemmings BA, Merlo A. Deltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival. PLoS One. 2013; 8: e57793. https://doi.org/10.1371/journal.pone.0057793 PMID: 23451269